Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ombudsman Probes Whether Industry Can Influence EMA In Pre-Submission Meetings

Executive Summary

The European Medicines Agency’s practice of holding pre-submission meetings with drug developers is being investigated by the European Ombudsman, who believes there is scope to make such interactions more transparent to tackle concerns over possible bias.

You may also be interested in...

Major Inquiry Into EMA Pre-Submission Meetings And Bias Risk Concludes

The European Ombudsman has recommended how the European Medicines Agency can avoid even the perception that the decisions it takes on marketing authorization applications are influenced by the pre-submission interactions it has with drug developers.

Search For Rasi's Successor At EMA Extended

The new head of the European Medicines Agency will need some solid leadership skills to steer the agency through the challenges of Brexit and to engage on issues including quality of innovation, affordability of medicines and improving patient access.

EMA Argues Pre-Submission Activities Under Ombudsman's Radar Are A Legal Requirement

The European Medicines Agency maintains it is fulfilling a legal obligation by organizing early interaction meetings with drug developers. The regulator is meeting with the EU Ombudsman, who is investigating whether such interactions can influence the agency’s decisions on marketing authorization applications.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts